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Abstract: Triple negative breast cancers (TNBC) without BRCA1/2 gene mutation or BRCAness are nowadays the 
breast malignancies most difficult to treat. Improvement of their treatment, for all phases of the disease, is an 
important unmet medical need. We analyzed the effect of homoharringtonine (HHT), a natural protein synthesis 
inhibitor approved for treatment of chronic myeloid leukemia, on four cell lines representing aggressive, BRCA1/2 
non-mutated, TNBC genomic categories. We show that HHT inhibits in vitro growth of all cell lines for more than 80%, 
after 48-72 h exposure to 20-100 ng/mL, the concentrations achievable in human plasma after subcutaneous ad-
ministration of the drug. HHT, at 100 ng/mL, strongly reduced levels of a major TNBC survival factor, anti-apoptotic 
protein Mcl-1, after only 2 h of exposure, in all cell lines except MDA-MB-231. Other anti-apoptotic proteins, Bcl-2, 
survivin and XIAP, were also strongly downregulated. Moreover, in vivo growth of the least sensitive cell line to HHT 
in vitro, MDA-MB-231, was inhibited for 36.5% in mice, by 1 mg/kg of the drug, given subcutaneously, bi-daily, over 
7 days. These results demonstrate marked antineoplastic activity of homoharringtonine in TNBC, making further 
development of the drug in this disease highly warranted.
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Introduction
Triple-negative breast cancer (TNBC) is today 
the breast cancer subtype most difficult to tr- 
eat, due to exquisite heterogeneity at the clini-
cal, phenotypic, genotypic and microenvironm- 
ental level [1]. Some TNBC subtypes are orphan 
diseases [2], whereas, in certain regions of the 
world, TNBC is a frequent, devastating cancer 
of young women, affecting reproductive and 
economic power of entire countries [3]. Current 
standard treatment for most TNBC patients is 
neoadjuvant chemotherapy (NACT), followed by 
breast surgery [4]. NACT leaves around two 
thirds of patients with residual disease, carry-
ing a risk for metastatic recurrences [5]. The 
armamentarium for systemic treatment of met-
astatic TNBC being very limited [6], patients in 
this phase of the disease have the worst prog-
nosis among all breast cancer patients, with 
overall survival often shorter than 12 months 
[7]. 
Therefore, improvement of TNBC treatment, for 
all disease phases, is still a big unmet medical 
need. However, after the initial success of an 
anticancer agent or regimen, TNBC, as many 
other cancers, frequently develops resistance. 
Efficacious, rapid and affordable ways to pre-
vent or/and combat that resistance need to be 
found. In such a situation, repositioning into 
TNBC treatment the drugs which have shown 
capacity to suppress other cancers, even after 
several prior treatments, is an approach that 
should not be neglected.
Homoharringtonine (HHT), also named omac-
etaxine mepesuccinate (international non-pro-
prietary name), is approved by the US FDA for 
treatment of patients with chronic myeloid leu-
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kemia (CML) resistant or intolerant to two or 
more tyrosine kinase inhibitors (TKI) [8]. HHT 
has been used in China for more than 50 years 
in treatment of pts with myeloid leukemias. 
Current regimens, which combine HHT with 
cytarabine and daunorubicin or aclarubicin, 
induce up to 85% of complete response in 
acute myeloid leukemia (AML), after only two 
cycles [9]. So, HHT is a potent anticancer agent, 
efficacious in several aggressive blood malig-
nancies, even in cases of resistance to specific, 
targeted therapy like TKI. HHT has recently 
been confirmed to efficaciously kill also the 
lung cancer cells with primary or TKI-induced 
resistance [10, 11].
HHT fixes to the ribosomes, disabling elonga-
tion of the nascent peptide chain and further 
protein synthesis [12]. The antileukemic actions 
of HHT are considered to be exerted principally 
by this mechanism, which occurs downstream 
all other ways of RNA translation inhibition [13]. 
Inhibition of protein synthesis by HHT has been 
shown to strongly reduce abundance of onco-
drivers (like Bcr-abl protein in CML) or other pro-
teins crucial for cancer cell survival [14].
Increased protein synthesis is present in can-
cers, both as a part of increased global ana-
bolic activity and as local adaptative event [15-
17]. In particular, resistance of cancer cell to 
death is enabled by increased abundance of 
anti-apoptotic proteins [18, 19]. One of them, 
Mcl-1, is a crucial determinant of breast cancer 
survival [20, 21]. Most TNBC have increased 
level of Mcl-1 protein, either due to the amplifi-
cation of MCL1 gene [22], or to hyperactivation 
of the PI3K-mTOR axis, found in up to 70% of 
cases [23]. An efficacious reduction of Mcl-1 
levels highly facilitates induction of cancer cell 
death by other anti-neoplastic agents [24]. This 
has encouraged development of several Mcl-1 
inhibitors [25-27], however none of them is 
approved yet for clinical use.
As several studies have shown rapid and 
marked reduction of Mcl-1 protein level by HHT 
in blood malignancies [28-30], we evaluated 
efficacity of this agent on the models of aggres-
sive TNBC. Here we are showing that HHT 
induces the same effect on TNBC in vitro as the 
one reported in blood cancers (leukemias, 
myeloma). In addition, HHT alone inhibits TNBC 
growth in mice after a short and easy to admin-
ister treatment (7 days, subcutaneous). These 
results support development of HHT in the 
treatment of TNBC patients, thus enlarging the 
area of exploitation of protein synthesis inhibi-
tion as an efficacious anticancer approach.
Material and methods
Cell lines and culture conditions
We used MDA-MB-231 (ATCC® HTB-26™), MDA- 
MB-468 (ATCC® HTB-132™), MDA-MB-157 
(ATCC® HTB-24™) and CAL-51, chosen to repre-
sent the BRCA1/2 non-mutated TNBC tran-
scriptomic subtypes [31]. The MDA lines were 
purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, USA). CAL-51 
was kindly provided by Dr Gerard Milano, from 
the Centre Antoine Lacassagne, Nice, France, 
where the line has been established [32]. The 
cell line stock vials were conserved at the 
Biological Resources Facility of Centre Jean 
Perrin (biobank ID BB-0033-00075, Clermont-
Ferrand, France). 
The MDA cell lines were cultured as previously 
described [33]. CAL-51 was maintained in 
DMEM, supplemented with 10% heat-inactivat-
ed fetal bovine serum and 20 mg/mL gentami-
cin (both media from Invitrogen Life Techno- 
logies, Carlsbad, CA, USA), in a humidified at- 
mosphere with 5% CO2.
HHT solution preparation 
Highly purified HHT of natural origin was sup-
plied by LeukePharma Inc. (Houston, TX, USA) 
in the form of water-soluble, crystalline tartar- 
ic acid salt. HHT-hydrogen (2R,3R)-(+)-tartrate 
(named below “HHT tartrate”; empirical formula 
C33H45NO15; extended formula C29H40NO9, 
C4H5O6; molecular weight 695.7 g/mol) was 
prepared from natural HHT by fractional crystal-
lization which yields HHT of the same purity 
level as the semi-synthetic form (US Patent WO 
2015101628 (2018) and related US patents). 
Initial stock solution of HHT tartrate was pre-
pared at 10 mM in sterile deionized water, ali-
quoted and kept at -80°C. For each experiment, 
a fresh HHT tartrate solution was prepared by 
dissolving the HHT tartrate stock in sterile 
phosphate-buffered saline.
Cell viability assay
Cell viability was assessed using the sulforho-
damine B (SRB) assay (Sigma-Aldrich, St Louis, 
MO, USA), as previously described [33]. Cells 
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were seeded in hexaplicates, in 96-well plates 
at 5 × 103 (MDA cell lines) or 1 × 103 cells/well 
(CAL-51). 
Cell cycle analysis
Cells were seeded into 6-well plates at 5 × 104 
cells per well (each cell line), left overnight to 
adhere, and then treated or not by 20-50 ng/
mL HHT for 48 h. The assay was further pre-
formed as previously described [33]. 
Apoptosis assay
Cell preparation was performed as in the cell 
cycle assays. The cells were treated by 20-100 
ng/mL of HHT for 6, 24, 48 or 72 hours. Ap- 
optosis measurement was performed by flow-
cytometry, as previously described [33]. 
Western blotting
Cells were plated in 10 cm Petri dishes at 5 × 
105 cells per dish, left overnight to adhere and 
treated, the following day, with 100 ng/mL of 
HHT over 2-48 h. Further processing, ending 
with the signal revelation was done as previ-
ously described [33]. The following primary 
antibodies were used: anti-Mcl-1 (clone D35A5), 
anti-Bcl-2 (50E3), anti-XIAP (D2Z8W), anti-sur-
vivin (71G4B7), anti-caspase 3 (8G10), anti-
PARP (rabbit polyclonal, cat. number 9542), 
anti-Myc (D84C12), anti-Akt (C67E7), anti-ph- 
ospho-Akt (D9E), anti-p44/p42 MAPK (rabbit 
polyclonal, cat. number 9102), anti-phospho-
p44/p42 MAPK (D13134E), anti-S6 ribosomal 
protein (5G10), anti-phospho-S6 ribosomal pro-
tein (D57.2.2E), anti-β-actin (D6A8), all from 
Cell Signaling Technology (Danvers, MA, USA). 
All antibodies were used at final concentration 
1:1000. The chemiluminescent signal detec-
tion was performed using a ChemiDoc XRS + 
gel imager (Bio-Rad). 
siRNA experiments
MDA-MB-468 and CAL-51 cells were seeded in 
6-well plates, at 2 × 105 cells and 2.5 mL of 
DMEM per well. After 24 h, the cells were trans-
fected by MCL1 siRNA and mock siRNA using 
Lipofectamine® (Invitrogen, ThermoFisher Sci- 
entific, Waltham, MA, USA). Briefly, the solution 
of MCL1 siRNA or mock siRNA were prepared 
by dissolving 3 µl of the respective reagents 
(ON-TARGETplus Human MCL1 siRNA and ON- 
TARGETplus Non-targeting siRNA, both from 
Dharmacon, Lafayette, CO, USA) in 150 µl of 
medium (Gibco®Opti-MEM™, Life Technologies, 
Carlsbad, CA, USA). Lipofectamine® RNAiMAX 
medium (9 µl) was also diluted in Opti-MEM™ 
(150 µl). Finally, the solution of each siRNA was 
added to the Lipofectamine solution, mixed 
well, and 250 µl of the mixture was added to 
the cells. The cells were then treated by 100 
ng/mL HHT for 24 h and 48 h, lysed, proteins 
extracted and western blots performed. 
Animal studies
The experiments were conducted according to 
the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes 
of Health (NIH Publication n°85-23, revised 
1996) and approved by the Ethic Committee of 
Clermont-Ferrand, France. All mouse studies 
were conducted in the animal facility of the 
INSERM U1240. Six weeks old Swiss nu/nu 
female mice were purchased from Charles 
River Laboratories France and housed in stan-
dard conditions (n = 5 per cage on ventilated 
racks, at 21-24°C, 60% humidity, 12 h light/12 
h dark cycle) with ad libitum access to irradiat-
ed food and water. 
For establishment of xenografts, groups of 10 
mice were injected subcutaneously, in the right 
flank area, with 1 × 107 MDA-MB-231 or 5 × 106 
MDA-MB-468 cells suspended in 150 μl of cul-
ture medium/Matrigel® (BD Biosciences, San 
Jose, CA, USA) in a 4:1 ratio. 
For assessment of HHT toxicity, groups of 6 
mice were injected with sterile saline water 
(0.9% NaCl) or 1, 2, 4 or 8 mg/kg of the drug, 
subcutaneously, bi-daily, over 7 days. The ani-
mals were left to rest 2 more days and sacri-
ficed at day 10. The solution for injection were 
freshly prepared by serial dilutions of the stock 
HHT-tartrate in sterile saline water and filtered 
through sterile filters having 0.25 µM pore size 
(Merck/Millipore, Burlington, MA, USA). The 
number of live animals was determined at days 
4, 8 and 10, after treatment initiation.
For evaluation of HHT efficacy in vivo, mice 
were randomized into the control or the treated 
group when xenografts reached a volume of 
200 ± 20 mm3. The MDA-MB-231 xenografts 
were treated by 1 mg/kg of HHT, using the 
same protocol as for determination of HHT tox-
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icity. The MDA-MB-468 xenografts were treat-
ed by 0.5 mg/kg, as 1 mg/kg was too toxic for 
the animals (all mice died after only a few days, 
in a preliminary experiment; data not shown). 
Tumor size was non-invasively assessed using 
a digital caliper on days 3, 6, 8 and 10 after 
treatment initiation. Tumor volume was calcu-
lated using the following formula: V = (length × 
width2)/2. 
The drug was evaluated in a total of 21 mice (2 
independent experiments on MDA-MB-231 tu- 
mors, with 8 or 9 mice per experiment, as well 
as in one experiment on MDA-MB-468 tumors, 
with 4 mice). Xenografting of CAL-51 cells was 
not successful, after several attempts.
Statistical analysis
The IC50 of HHT after 24, 48 or 72 h were 
determined by the Chou-Talalay method [34], 
using Compusyn software (freely downloadable 
from www.combosyn.com). Mean ± standard 
deviation was used for presentation of all val-
ues. Variations of the viable or apoptotic cell 
fraction according to cell type, exposure time or 
drug concentration were studied using two-way 
ANOVA. Comparison of mean values between 
two time-points was tested by Kruskal-Wallis 
H-test because distributions were not Gaussian 
or heteroscedastic. Tests were two-sided and 
the standard level P ≤ 0.05 was considered sta-
tistically significant.
Results
HHT inhibits growth of TNBC cell lines, in con-
centrations achievable in patients’ plasma
As shown on Figure 1A, inhibitory effect of HHT 
on TNBC cell growth in vitro was observed 
already after 24 h. At that time, IC50 were 15.7 
ng/mL, 19.9 ng/mL, 23.1 ng/mL and 80.5 ng/
mL, for MDA-MB-157, MDA-MB-468, CAL-51 
and MDA-MB-231, respectively. IC50 for the 
first three cell lines are below the lowest con-
centration of HHT (31.3 ng/mL), found 5 days 
after the last injection, in plasma of AML pa- 
tients treated subcutaneously, bi-daily, by 5 
mg/m2 for 9 days [35]. IC50 for MDA-MB-231 is 
comparable to the maximal plasmatic concen-
tration of HHT found in patients, at the same 
time point, after the same regimen. 
HHT effect on cell line growth was dose- but not 
time-dependent in MDA-MB-157, MDA-MB-468 
and CAL-51 (no significant change of IC50 after 
48 h or 72 h, P > 0.05, Figure 1B and 1C). Ho- 
wever, growth inhibition on MDA-MB-231 cells 
was both dose- and time-dependent: concen-
trations below 50 ng/mL could not significantly 
reduce cell growth, even after 72 h. However, 
when MDA-MB-231 was exposed to higher con-
centrations of HHT, the viable fraction (VF) was 
significantly lower after 72 h, compared to 24 h 
(at 50 ng/mL, VF: 25.9 ± 2.4% vs 58.1 ± 14.5%, 
72 h vs 24 h resp., P < 0.01; at 100 ng/mL, VF: 
Figure 1. Cell viability after exposure to homo-
harringtonine in vitro. HHT, homoharringtonine; 
VF, viable fraction. As HHT-tartrate is soluble in 
water, the control samples were omitted the drug 
and the volume was replaced with the culture 
media. The concentrations are given as the HHT 
equivalent in HHT tartrate. The values represent 
a mean ± SD of three independent experiments.
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Figure 2. Distribution of cells in the cell cycle phases after exposure to homoharringtonine for 48 h. HHT, homoharringtonine. As HHT-tartrate is soluble in water, the 
control samples were omitted the drug and the volume was replaced with the culture media. The concentrations are given as the HHT equivalent in HHT tartrate. 
The figure represents the most representative of three independent experiments.
Homoharringtonine in triple negative breast cancer
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18.7 ± 4.8% vs 41.7 ± 13.3%, 72 h vs 24 h, P < 
0.01, Figure 1A and 1C). Thus, the viable frac-
tion of MDA-MB-231 cells, after 72 h of expo-
sure to high concentrations of HHT, was similar 
to the viable fractions in other cell lines (Figure 
1C). 
Taken together, these results indicate that HHT, 
in vitro, strongly inhibits (more than 80%) gr- 
owth of TNBC cells with different molecular 
characteristics (3 transcriptomic subtypes: me- 
senchymal (CAL-51), mesenchymal stem-like 
(MDA-MB-157 and MDA-MB-231, basal-like 1 
(MDA-MB-468) [31]).
To get a better insight into cell growth-inhibitory 
action of HHT, we first analyzed changes in the 
size of cell populations engaged in different 
phases of the cell cycle, after 48 h-exposure to 
20-100 ng/mL of the drug. As shown on Figure 
2B and 2D, HHT, already at 20 ng/mL, induced 
accumulation in the G1 (MDA-MB-157) or/and 
in the S- and G1-phase (CAL-51). Under such 
conditions, MDA-MB-468 and MDA-MB-231 
cells were first arrested in the G2/M phase; a 
stronger arrest occurred at 50 ng/mL (Figure 
2A and 2C). The maximal concentration of HHT, 
100 ng/mL, arrested both MDA-MB-468 and 
MDA-MB-231 cells in the S- and G1-phase of 
the cell cycle (Figure 2A and 2C). 
HHT induces apoptosis of TNBC cells, in cell-, 
dose- and time-dependent manner
We next evaluated the capacity of HHT to 
induce apoptosis in TNBC cell lines, as well as 
the kinetics of that phenomenon, knowing that 
in blood malignancies HHT can induce cell 
death as early as after 3-4 hours of exposure 
[28-30].
As shown on Figure 3, the four analyzed cell 
lines showed different levels of apoptosis after 
exposure to 20-100 ng/mL of the drug, over a 
time course from 6 to 72 h. MDA-MB-231 cells 
were most resistant to apoptosis induction: the 
total apoptotic fraction (AF) did not exceed 
11.6 ± 3.6% at any concentration and at any 
time point (Table 1). In other three cell lines 
(MDA-MB-157, MDA-MB-468 and CAL-51) the 
AF was cell type-dependent (P = 0.0016): MDA-
MB-157 cells were markedly more sensitive to 
the apoptosis induction than MDA-MB-468 and 
CAL-51 cells, as the mean value of AF obtained 
by all drug concentrations, at all time-points, 
was twice higher in MDA-MB-157 cells (44.9%) 
than the corresponding mean value obtained 
either in MDA-MB-468 (18.4%) or in CAL-51 
cells (21.2%) (P = 6.5 × 10-5 for MDA-MB-157 
vs MDA-MB-468 and P = 1.4 × 10-3 for MDA-
MB-157 vs CAL-51). 
The apoptotic effect of HHT was dose- and 
time-dependent in cells other than MDA-
MB-231 (Figure 3). The total AF in MDA-MB-157 
cells, after the lowest drug concentration test-
ed, 20 ng/mL, was 21.9 ± 1.6% already after 6 
h of exposure, and reached the maximum, 82.4 
± 2.5%, after 72 h of exposure to 100 ng/mL. In 
CAL-51 and MDA-MB-468 cells the total AF was 
11.0 ± 2.6% and 12.1 ± 2.3%, respectively, 
after the lowest concentration and the shortest 
exposure, and reached 46.0 ± 3.4% and 32.5 ± 
5.7% after maximal concentration and expo-
sure time (Table 1).
The cell lines other than MDA-MB-231 also dif-
fered in kinetics of apoptosis induction. Indeed, 
apoptosis occurred most rapidly in MDA-MB- 
157 cells, in which AF more than doubled from 
6 h to 24 h of exposure to any concentration 
(Figure 3A; Table 1). When incubated with 
20-50 ng/mL of HHT, CAL-51 cells showed a 
steady rise in AF over 72 h, however, after expo-
sure to 100 ng/mL, the AF reached its maxi-
mum already after 48 h and did not exceed that 
level during next 24 h (Figure 3B; Table 1). 
Similar kinetics of apoptosis induction was 
observed in MDA-MB-468 cells (Figure 3C; 
Table 1).
The difference in AF size between MDA-MB-157 
and CAL-51 cells, after exposure to 100 ng/mL 
of HHT during 48 h (73.9 ± 4.6% vs 44.2 ± 
3.5%, respectively; Table 1) corresponded to 
the difference in size of the G0/G1 fraction in 
those cells (74.6% vs 57.4%, respectively/data 
not shown, Figure 2B and 2D). The MD-MB-468 
cells were more arrested in the G0/G1 phase 
Figure 3. Apoptotic fractions in the cell lines exposed to homoharringtonine. HHT, homoharringtonine; AF, apoptotic 
fraction; T0, beginning of the experiment (before adding the drug). As HHT tartrate is soluble in water, the control 
samples were omitted the drug and the volume was replaced with the culture media. The concentrations are given 
as the HHT equivalent in HHT tartrate. The values represent a mean ± SD of three independent experiments.
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Figure 4. Levels of anti-apoptotic proteins in cell lines exposed to homoharringtonine. ctl, control, beginning of the 
experiment (before adding the drug). All cells were incubated with 100 ng/ml of HHT. The figure represents the most 
representative of three independent experiments.
Table 1. Apoptotic fractions in TNBC cell lines exposed to homoharringtonine 
HHT (ng/ml) AF
T0 T6 T24
0 0 20 50 100 0 20 50 100
MDA-MB-157
Early 9.1 ± 4.2 8.9 ± 4.0 14.7 ± 3.0 21.8 ± 3.1 23.7 ± 4.5 13.6 ± 2.1 36.2 ± 3.3 38.6 ± 2.8 48.2 ± 3.5
Late 4.7 ± 2.2 5.9 ± 1.6 7.2 ± 1.9 8.2 ± 0.6 12.6 ± 1.8 5.5 ± 1.3 12.7 ± 1.5 17.3 ± 3.3 21.1 ± 1.6
Total 13.7 ± 4.7 14.8 ± 3.7 21.9 ± 1.6 30.0 ± 3.2 36.3 ± 2.7 19.1 ± 3.3 48.9 ± 4.8 55.9 ± 0.5 69.3 ± 4.1
MDA-MB-468
Early 5.2 ± 1.7 7.4 ± 1.2 8.3 ± 1.4 12.1 ± 4.1 14.7 ± 4.5 7.2 ± 0.8 9.5 ± 1.3 14.4 ± 4.9 18.1 ± 5.5
Late 2.7 ± 1.2 4.4 ± 1.1 3.8 ± 0.9 3.8 ± 0.5 4.6 ± 0.9 2.7 ± 0.9 3.5 ± 1.7 4.5 ± 0.7 6.2 ± 0.6
Total 7.9 ± 2.8 11.8 ± 1.7 12.1 ± 2.3 15.9 ± 4.2 19.2 ± 3.8 9.9 ± 1.5 13.0 ± 2.8 19.0 ± 5.4 24.3 ± 5.7
MDA-MB-231
Early 2.7 ± 0.5 2.2 ± 0.5 2.8 ± 1.2 3.0 ± 0.7 4.2 ± 1.7 2.6 ± 0.7 3.4 ± 1.0 6.0 ± 1.6 4.6 ± 1.3
Late 2.4 ± 1.0 2.8 ± 1.0 2.7 ± 0.5 2.9 ± 0.8 3.5 ± 1.1 2.8 ± 0.8 2.3 ± 0.2 5.6 ± 2.3 4.2 ± 1.8
Total 5.1 ± 1.4 5.0 ± 1.4 5.5 ± 1.7 6.0 ± 0.9 7.7 ± 2.1 5.5 ± 1.2 5.7 ± 1.0 11.6 ± 3.6 8.8 ± 1.8
CAL-51
Early 4.2 ± 1.0 7.4 ± 1.6 7.2 ± 1.8 7.8 ± 2.0 9.1 ± 2.8 5.3 ± 1.5 11.6 ± 2.8 16.9 ± 0.7 15.5 ± 1.3
Late 4.4 ± 2.0 1.9 ± 2.2 3.8 ± 0.9 3.9 ± 0.9 5.4 ± 1.2 3.7 ± 1.2 3.6 ± 0.1 5.1 ± 0.6 6.1 ± 1.0
Total 8.6 ± 1.1 9.3 ± 0.7 11.0 ± 2.6 11.7 ± 2.6 14.5 ± 2.8 9.0 ± 1.2 15.2 ± 2.8 22.0 ± 0.2 21.6 ± 1.1
HHT (ng/ml) AF
T48 T72
0 20 50 100 0 20 50 100
MDA-MB-157
Early 14.6 ± 3.8 39.4 ± 2.7 48.8 ± 2.8 53.9 ± 4.2 9.9 ± 2.7 45.5 ± 3.9 53.7 ± 4.6 56.3 ± 3.0
Late 5.1 ± 1.3 15.2 ± 1.9 19.7 ± 0.6 20.0 ± 4.6 6.4 ± 2.5 17.5 ± 2.8 22.0 ± 4.6 26.1 ± 1.2
Total 19.7 ± 3.7 54.6 ± 3.9 68.5 ± 2.8 73.9 ± 4.6 16.3 ± 4.7 62.9 ± 1.1 75.7 ± 4.0 82.4 ± 2.5
MDA-MB-468
Early 8.3 ± 1.2 14.5 ± 3.3 17.6 ± 4.1 21.9 ± 5.8 8.7 ± 1.2 17.1 ± 4.1 23.6 ± 5.5 27.5 ± 4.5
Late 3.8 ± 1.3 6.3 ± 0.2 6.4 ± 0.9 6.3 ± 1.5 3.6 ± 0.5 6.0 ± 0.2 4.6 ± 1.8 5.0 ± 1.3
Total 12.1 ± 1.7 20.7 ± 3.5 24.0 ± 3.2 28.3 ± 6.0 12.3 ± 0.8 23.1 ± 4.1 28.2 ± 6.1 32.5 ± 5.7
MDA-MB-231
Early 2.2 ± 0.9 3.5 ± 1.7 5.4 ± 1.4 5.8 ± 1.3 2.3 ± 1.0 3.2 ± 2.1 4.4 ± 2.2 4.1 ± 1.3
Late 1.5 ± 0.4 3.7 ± 2.2 4.4 ± 1.0 4.2 ± 1.8 2.4 ± 1.2 2.8 ± 1.0 2.9 ± 0.7 3.2 ± 0.2
Total 3.7 ± 0.5 7.2 ± 3.1 9.8 ± 1.5 10.0 ± 0.5 4.7 ± 1.7 6.0 ± 2.8 7.3 ± 2.9 7.4 ± 1.4
CAL-51
Early 5.5 ± 0.8 16.0 ± 2.8 24.4 ± 2.7 35.6 ± 4.2 4.7 ± 1.4 25.0 ± 2.9 33.6 ± 4.4 37.6 ± 4.0
Late 3.9 ± 0.3 5.8 ± 0.5 6.9 ± 0.4 8.6 ± 1.1 4.3 ± 1.7 8.4 ± 0.9 8.5 ± 1.4 8.4 ± 1.2
Total 9.4 ± 0.7 21.8 ± 2.6 31.3 ± 3.1 44.2 ± 3.5 9.1 ± 2.5 33.5 ± 2.1 42.1 ± 2.9 46.0 ± 3.4
AF, apoptotic fraction; HHT, homoharringtonine; T0, start of the experiment; T6, after 6 h of exposure; T24, after 24 h of exposure; T48, after 48 h of exposure; T72, after 
72 h of exposure. All values are given in percentages (%) and represent mean ± SD of three independent experiments.
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HHT rapidly reduces abun-
dance of several anti-apop-
totic proteins, in particular 
of Mcl-1, which precedes 
apoptosis onset
As previous reports demon-
strated that HHT most im- 
pacts the short-lived cellu-
lar proteins [28-30], we in- 
vestigated how exposure to 
this drug affects abunda- 
nce of several anti-apoptot-
ic proteins, known to have a 
short half-life [36].
As shown on Figure 4, HHT 
provoked an extremely ra- 
pid and strong reduction of 
Mcl-1 levels (almost to total 
loss, after only 2 h of expo-
sure) in all cell lines except 
in MDA-MB-231. Similar re- 
duction of Bcl-2 was obs- 
erved in MDA-MB-468 ce- 
lls. In addition, survivin le- 
vel was strongly and rapi- 
dly reduced in CAL-51 and 
MDA-MB-468 cells. XIAP 
abundance diminished as 
well, in all cells except MDA-
MB-231, however the red- 
uction was visible after a 
longer exposure to HHT. 
Levels of caspase 3, the 
main apoptosis effector pr- 
otein, started to lower sev-
eral hours after the moment 
when Mcl-1 was almost un- 
detectable. PARP1 change 
had similar kinetics (Figure 
4).
(61.9%, data not shown) than apoptotic (AF = 
28.3 ± 6.0%, Table 1). In MDA-MB-231 cells, 
despite a similar cell cycle arrest like in CAL-51 
cells after 100 ng/mL for 48 h (Figure 2A), 
apoptotic fraction was much smaller (Figure 
3D). On that basis, we conclude that, in MDA-
MB-157, CAL-51 and MDA-MB-468 cells, apop-
tosis likely takes place in the G1/G0-phase of 
the cell cycle. However, HHT effect on MDA-
MB-231 cells is mostly cytostatic (arrest in the 
S-phase) and not cytotoxic.
We next compared Mcl-1 abundance reduction 
obtained by exposure to HHT or to MCL1 small 
inhibiting RNA (siRNA). As shown on Figure 5, in 
both CAL-51 and MDA-MB-468 cell line, the 
exposure to either siRNA or to 100 ng/mL of 
HHT resulted in a strong reduction of Mcl-1 lev-
els, already after 2 h. Addition of HHT, after 24 
h incubation with MCL1 siRNA, further lowered 
Mcl-1 levels, in both cell lines, and already after 
2 h of incubation (Figure 5). In CAL-51 cells, 
level of Mcl-1 was reduced practically to zero, 
Figure 6. Myc protein level after exposure of cell lines to homoharringtonine. ctl, 
control, beginning of the experiment (before adding the drug). All cells were in-
cubated with 100 ng/ml of HHT. The figure represents the most representative 
of two independent experiments.
Figure 7. Determination of Maximal Tolerated Dose of homoharringtonine in 
mice after subcutaneous bi-daily administration over 7 days. D0, beginning of 
the experiment; D4, D8, D10, days 4, 8 and 10 after the treatment start.
Figure 5. Mcl-1 protein level after exposure of cell lines to MCL1 siRNA, to ho-
moharringtonine or to both components. ctl, control, beginning of the experi-
ment (before adding the drug); HHT, homoharringtonine. All cells were incu-
bated with 100 ng/ml of HHT. The figure represents the most representative of 
two independent experiments.
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either by 100 ng/mL of HHT alone, by siRNA or 
by both agents together, after 24 h of exposure 
(Figure 5). Interestingly, under identical condi-
tions, in MDA-MB-468 cells there is still a resid-
ual quantity of Mcl-1 protein after 24 h of treat-
ment with MCL1 siRNA only (Figure 5). 
These results demonstrate that exposure to 
HHT in vitro reduces Mcl-1 protein level more 
effectively than one of the most powerful ways 
to achieve that effect, inhibition by siRNA of the 
gene which encodes for the protein (MCL1).
HHT rapidly and strongly reduces Myc levels, 
even in MDA-MB-231 cells
After observation that HHT reduced abundance 
of major anti-apoptotic proteins in all cells but 
MDA-MB-231, we wanted to see whether it will 
reduce abundance of a short-lived protein not 
from the anti-apoptotic class. For example, Myc 
protein has a very short half-life [37] and an 
important role in TNBC resistance to therapy 
[22, 38].
As shown on Figure 6, in each MDA-MB-231 
and CAL-51 cells HHT strongly reduced Myc lev-
els already after 2 h. At that time, in MDA-
MB-231 cells, Myc levels were reduced almost 
to zero and did not increase after (Figure 6).
HHT inhibits growth of MDA-MB-231 and MDA-
MB-468 in vivo
As shown on Figure 7, the Maximal Tolerated 
Dose (MTD) of HHT, in a 7-day regimen, was 2 
mg/kg (two subcutaneous injections, each with 
1 mg/kg) per day, for the mice carrying MDA-
MB-231 xenografts. 
HHT had a growth-suppressive effect on MDA-
MB-231 xenografts, in two experiments. In the 
first (Figure 8), the mean volume of the tumors 
in the treated animals was, at the end of obser-
vation (day 10), for 12% smaller than in the 
untreated animals (184.4 mm3 vs 209.5 mm3, 
treated vs untreated, respectively, Figure 8E). 
Moreover, the mean tumor volume before the 
initiation of the treatment by was almost twice 
bigger in the group that will be treated by HHT 
than in the group planned for treatment with 
saline only (304.5 mm3 vs 173.3 mm3, respec-
tively). In the second experiment (Figure 9), 
with less difference in tumor volume before ini-
tiation of the treatment, the mean tumor vol-
ume, at day 10, was reduced for 36.5% in the 
treated animals, compared to the untreated 
group (146.2 ± 15.5 mm3 vs 230.4 ± 27.7 mm3, 
respectively, Figure 9E).
In the experiment on MDA-MB-468 xenografts 
(Figure 10), the mean tumor volume, at day 10, 
was for almost half-smaller in the treated mice 
than in the untreated ones (142.8 ± 22.5 mm3 
vs 273.8 ± 110.5 mm3, respectively, Figure 
10E).
The difference in animal weight after treat-
ment, in comparison to the weight before treat-
ment, was minimal (Figures 9 and 10, panels C 
and D on each).
Taken together, these results indicate that HHT 
inhibits in vivo growth of two different models 
of aggressive TNBC, without general toxicity for 
the animals, when administered in a 7-day re- 
gimen.
Discussion
Here we report that an approved anti-leukemic 
agent, HHT/omacetaxine [8], has a growth-
reducing effect on one of the most aggressive 
solid cancers, TNBC. This is the first study of 
HHT alone using transcriptomically defined, 
BRCA1/2 non-mutated TNBC models. These 
models represent the TNBC subgroups nowa-
days most in need of new treatment approach-
es, as the currently available standard chemo-
therapy, as well as the most promising new 
agents, PARP or immune checkpoint inhibitors, 
all work best in TNBC with defects in DNA dam-
age repair (BRCA1/2-mutated or with BRC- 
Aness) [4].
HHT has been principally evaluated in blood 
malignancies and not in solid tumors. A couple 
of early clinical trials, which tested HHT in the 
form of leaf extract, reported no effect of this 
molecule on breast cancer [39, 40]. Very re- 
Figure 8. Effect of bi-daily subcutaneous administration of 1 mg/kg homoharringtonine over 7 days on MDA-MB-231 
xenografts in mice (experiment 1). A and B: Tumor volumes, absolute values. C: Tumor volume before and after 
treatment, mean ± SD. D and E: Mouse weight, absolute values. CTL, control, mice treated with saline water only; 
HHT, homoharringtonine; D0, beginning of the experiment; D10, day 10 after the treatment start. 
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cently, a natural analog of HHT, isoharringto-
nine, was reported to inhibit growth and migra-
tion of two TNBC cell lines, one BRCA1-mutated, 
and another highly sensitive to a standard che-
motherapeutic component, paclitaxel [41]. That 
indicates inhibitory action of the harringtonine 
class components on the TNBC already well 
responding to the classical chemotherapy. Our 
study demonstrates that HHT also suppresses 
growth of the TNBC strains quite resistant to 
the available chemotherapy drugs [31]. In addi-
tion, IC50 of HHT were at the low-medium nano-
molar level (after 72 h of incubation, from 7 to 
45 ng/mL /data not shown/, which is equiva-
lent to 13 to 82.5 nM, molecular weight of HHT 
being 545.6 g/mol). Similar IC50 have been 
seen in myeloid leukemia cell lines [28], indi-
cating that HHT is a potent anti-neoplastic 
agent.
We showed that HHT very rapidly induces sig-
nificant growth inhibition and cell death in 3 out 
of 4 cell TNBC cell lines tested. This is in con-
cordance with studies performed on AML and 
myeloma cell lines, in which HHT induced apop-
tosis of malignant cells as early as after 4-6 h 
of incubation [28, 29, 42, 43]. In our study, HHT 
exerted the maximal apoptotic effect after a 
continuous exposure for 48-72 h, depending on 
the cell type. HHT is highly stable in cell cul-
tures [44], so the experimental conditions we 
used are an example of continuous exposure to 
the drug. In patients, HHT gets progressively 
degraded; its mean steady-state half-life is 
around 7 h [45], which, in the bi-daily regimens, 
can assure exposure of cancer cells to suffi-
cient concentration of the drug to permit its 
anti-cancer action.
Induction of apoptosis by HHT occurred after 
an arrest of TNBC cells in the cell cycle. In one 
of the TNBC cell lines we tested, MDA-MB-231, 
HHT dominantly induced an S-phase arrest, 
without much apoptosis. However, we observed 
a significant reduction in MDA-MB-231 tumor 
volume after 7 days of HHT treatment in vivo. 
This discrepancy between in vitro and in vivo 
data could be explained by experimental de- 
sign: in our in vitro studies, the maximal expo-
sure time to HHT was 48 h (cell cycle) or 72 h 
(apoptosis), whereas in vivo it was 7 days, plus 
additional 2 days, without the treatment, before 
the measure of tumor volume. That way the 
tumor cells were, in vivo, exposed to HHT for 
almost 5-fold longer time then in vitro. Even 
during the 2 days without the drug, in vivo, HHT 
which has already entered the cells and fixed to 
ribosomes, could continue inhibiting the pro-
tein synthesis and tumor growth. Indeed, there 
was no difference in the MDA-MB-231 tumor 
volume after 3 days of HHT injection, but it 
became visible after 6 days and was maximal 
after 10 days (Figure 7). 
We could not test HHT on sufficient number of 
mice carrying xenografts of MDA-MB-468 and 
CAL-51 cell line, so we cannot make a strong 
conclusion about its efficiency in those models. 
Anyway, a remarkable growth-inhibitory effect 
of HHT was demonstrated in 4 mice carrying 
MDA-MB-468 xenografts. As we showed that 
HHT does reduce in vivo growth of the cell line 
the least sensitive in vitro (MDA-MB-231), it 
seems plausible to hypothesize that it would 
inhibit in vivo growth of the cell lines it most 
inhibited in vitro (CAL-51, MDA-MB-157, MDA-
MB-468). However, that remains to be proven 
in future studies.
MDA-MB-468 and CAL-51 cell lines have in 
common hyperactivated PI3K-AKT-mTOR path-
way, due to PTEN absence in the former and 
PIK3CA activating mutation in the latter [31]. 
These cell lines may have an increased RNA 
translation/increased protein synthesis so its 
inhibition may have a deleterious effect on their 
growth. We observed, on a luminal breast can-
cer cell line MCF-7, a growth-inhibitory effect of 
HHT similar to the one observed on MDA-
MB-468 cells (in vitro data, not shown). MCF-7 
also carries an activating mutation of PIK3CA, 
and the increased sensitivity of that cell line to 
HHT indicates that the drug could be effica-
cious in suppression of all breast cancers hav-
ing the PI3K-AKT-mTOR pathway activated, at 
least if the activation is caused by a PI3K acti-
vating mutation or PTEN loss, irrespective of 
molecular subtype. 
Figure 9. Effect of bi-daily subcutaneous administration of 1 mg/kg homoharringtonine over 7 days on MDA-MB-231 
xenografts in mice (experiment 2). A and B: Tumor volumes, absolute values. C: Tumor volume before and after 
treatment, mean ± SD. D and E: Mouse weight, absolute values. CTL, control, mice treated with saline water only; 
HHT, homoharringtonine; D0, beginning of the experiment; D3, D6, D8, D10, day 3, 6, 8 and 10 after the treatment 
start.
Homoharringtonine in triple negative breast cancer
1056 Am J Cancer Res 2019;9(5):1043-1060
Homoharringtonine in triple negative breast cancer
1057 Am J Cancer Res 2019;9(5):1043-1060
We hypothesize that the strong and rapid Mcl-1 
protein level reduction, is the main event which 
induces apoptosis of TNBC after exposure to 
HHT. Our experiments showed that a significant 
reduction of Mcl-1 protein level, either by HHT 
or by sRNA, is rapidly followed by apoptosis 
induction. Mcl-1 protein has been demonstrat-
ed to have crucial importance for TNBC survival 
[21]. In addition, overexpression of Mcl-1 is 
associated with worse survival of pts with all 
breast cancer subtypes [20]. Finally, downregu-
lation of Mcl-1 levels enables sensitization of 
breast cancer cells to the current chemothera-
py [46]. However, all reported Mcl-1 inhibitors 
are far earlier in the clinical development than 
HHT, which has already been approved in one 
malignant disease [8]. 
HHT is a universal inhibitor of protein synthesis 
in eukaryotes, and, as many natural products, 
can be considered as a multi-target agent, 
although all its action targets are now known. It 
has been demonstrated that HHT inhibits stem 
cells of chronic myeloid leukemia and multiple 
myeloma [47, 48]. In TNBC, HHT-induced down-
regulation of Myc protein may also have an 
important role in stem cell suppression [49]. 
We demonstrated that HHT rapidly reduces 
Myc abundance to very low levels even in a 
highly metastatic TNBC cell line, MDA-MB-231. 
This implies that HHT might be efficacious in 
suppression of TNBC metastatic progression. 
We showed, in two independent experiments, 
that HHT markedly suppresses in vivo growth of 
MDA-MB-231. In additional experiments, which 
need verification, we also observed that migra-
tion of this line was strongly inhibited by HHT 
(data not shown), indicating possible anti-meta-
static properties of the drug.
In conclusion, our results show that HHT effec-
tively suppresses an important mechanism of 
cancer cell resistance to death, the increased 
levels of Mcl-1 and other anti-apoptotic pro-
teins. As it has been shown that Mcl-1 down-
regulation is of primordial importance for sensi-
tization to many anti-cancer therapies, HHT is 
worth developing in TNBC, as a single agent in 
the metastatic phase of the disease and as a 
sensitizer of standard chemo- or targeted ther-
apy. Development of another natural product 
(HHT) for breast cancer therapy should be 
encouraged by the eribulin case, recently 
approved as a single agent in metastatic breast 
cancer and one of the most efficacious treat-
ments in this setting. In addition, new purifica-
tion procedures (like the one exploited for pro-
duction of HHT used in this study) which yield a 
highly purified HHT form at a several-fold lower 
cost compared to semi-synthesis used for pro-
duction of the currently approved omacetaxine 
(personal communication, LeukePharma Inc.). 
This will render HHT and translation/protein 
synthesis inhibition more available for cancer 
treatment, and in particular, in the regions wh- 
ere TNBC and other cancers are devastating 
the population but numerous patients cannot 
afford even the standard chemotherapy.
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